Stapokibart

Phase 3Biologic

CChengdu Kangnuoxing Biopharma,Inc.

Stapokibart is one of 98 biologic programs targeting Non-Allergic Rhinitis. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Non-Allergic RhinitisActive, not recruiting

AmyloidosisActive, not recruiting

Bullous PemphigoidNot yet recruiting

Allergic RhinitisRecruiting

Prurigo NodularisActive, not recruiting

Seasonal Allergic RhinitisRecruiting

Chronic Rhinosinusitis With Nasal PolypsNot yet recruiting

Non-Allergic RhinitisPreclinical

Active, not recruiting

AmyloidosisPreclinical

Active, not recruiting

Bullous PemphigoidPhase 3

Not yet recruiting

Allergic RhinitisPhase 2

Recruiting

Prurigo NodularisPhase 3

Active, not recruiting

Seasonal Allergic RhinitisPhase 3

Recruiting

Chronic Rhinosinusitis With Nasal PolypsPhase 3

Not yet recruiting

Competition

Competitive Landscape

52 competitors in Allergic Rhinitis

#DrugCompanyPhaseTrials

Singulair

OOrganon and Co

Approved

13 2

Flovent

PParatek Pharmaceuticals Inc

Approved

12 3

Xyzal

CChattem

Approved

11 4

Alvesco

AAzurity Pharmaceuticals

Approved

8 5

Claritin

PPerrigo Company

Approved

6 6

Clarinex

OOrganon and Co

Approved

5 7

Zyrtec

KKenvue Brands

Approved

5 8

Pulmicort

SSalix

Approved

5 9

Qvar

SSchering-Plough

Approved

4 10

Allegra

CChattem

Approved

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2026

Phase 3Recruiting

Seasonal Allergic Rhinitis

NCT07678931

N/ANot yet recruiting

Amyloidosis

NCT07143864

Q1 2027

N/ANot yet recruiting

Non-Allergic Rhinitis

NCT07240376

Q1 2028

Not yet recruiting

Seasonal Allergic Rhinitis

NCT07459556

Not yet recruiting

Chronic Rhinosinusitis With Nasal Polyps

NCT07483268

Q2 2028

Phase 3Not yet recruiting

Bullous Pemphigoid

NCT07210554

Clinical

Trials by Indication[1]

Seasonal Allergic Rhinitis2 trials

A Prospective Study of Stapokibart Injection in Patients With Seasonal Allergic Rhinitis (SAR)

Not yet recruiting·CChengdu Kangnuoxing Biopharma,Inc.··NCT07459556·400 enrolled

A Multicenter, Randomized, Double-Blind, Placebo-Controlled Clinical Study to Evaluate the Efficacy and Safety of Stapokibart Injection in Adolescent Patients With Seasonal Allergic Rhinitis Receiving Background Therapy

Recruiting·CChengdu Kangnuoxing Biopharma,Inc.·Phase 3·NCT07678931·136 enrolled

Chronic Rhinosinusitis With Nasal Polyps2 trials

A Study of Stapokibart Injection in Patients With Chronic Rhinosinusitis With Nasal Polyps (CRSwNP) .

Not yet recruiting·CChengdu Kangnuoxing Biopharma,Inc.··NCT07483268·600 enrolled

A Cohort Study on Biomarkers to Predict the Efficacy of Biologics for Chronic Rhinosinusitis with Nasal Polyps

Not yet recruiting·—·Phase 4·NCT06801353·90 enrolled

Amyloidosis1 trial

Efficacy and Safety of Stapokibart for Primary Cutaneous Amyloidosis

Not yet recruiting·FFirst Affiliated Hospital of Chongqing Medical University·N/A·NCT07143864·40 enrolled

Prurigo Nodularis1 trial

Study on the Treatment of Prurigo Nodularis With Stapokibart Injection

Active, not recruiting·KKeymed Biosciences Co.Ltd·Phase 3·NCT06424470·200 enrolled

Allergic Rhinitis1 trial

Study of Stapokibart Injection in Patients With Allergic Rhinitis

Recruiting·KKeymed Biosciences Co.Ltd·Phase 2·NCT06525597·120 enrolled

2 more indications

Bullous Pemphigoid1 trial

Study of Stapokibart Injection in Subjects With Moderate to Severe Bullous Pemphigoid

Not yet recruiting·CChengdu Kangnuoxing Biopharma,Inc.·Phase 3·NCT07210554·200 enrolled

Non-Allergic Rhinitis1 trial

Efficacy and Safety of Stapokibart in Non-Allergic Rhinitis With Eosinophilia Syndrome

Not yet recruiting·HHuazhong University of Science and Technology·N/A·NCT07240376·90 enrolled

Sources

References

[1]
ClinicalTrials.gov — 9 trial records for Stapokibart. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Stapokibart compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Stapokibart. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Chengdu Kangnuoxing Biopharma,Inc. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Biologic[2]
Highest Phase: Phase 3[1]
Company: CChengdu Kangnuoxing Biopharma,Inc.

Stapokibart

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2026

Q1 2027

Q1 2028

Q2 2028

Trials by Indication[1]

Seasonal Allergic Rhinitis2 trials

Chronic Rhinosinusitis With Nasal Polyps2 trials

Amyloidosis1 trial

Prurigo Nodularis1 trial

Allergic Rhinitis1 trial

Bullous Pemphigoid1 trial

Non-Allergic Rhinitis1 trial

References

Drug Info

Quick Facts

Related News